Weekly Research Analysts’ Ratings Updates for Generate Biomedicines (GENB)

A number of firms have modified their ratings and price targets on shares of Generate Biomedicines (NASDAQ: GENB) recently:

• 9/12/2026 – Generate Biomedicines was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/8/2026 – Generate Biomedicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
• 8/29/2026 – Generate Biomedicines was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/28/2026 – Generate Biomedicines had its price target raised by HC Wainwright from $25.00 to $30.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Generate Biomedicines is now covered by Weiss Ratings. They set a “sell (d)” rating on the stock.
• 8/8/2026 – Generate Biomedicines was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/25/2026 – Generate Biomedicines was upgraded by Wall Street Zen from “sell” to “hold”.

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and machine learning to discover and design protein-based medicines. Its technology is intended to model relationships among protein sequences, structures and biological functions, helping researchers create therapeutic proteins with desired characteristics.

The company’s research activities are focused on developing novel biologic medicines for areas of significant unmet medical need, including oncology, immunology, infectious diseases and rare diseases.